Strategic Transformation of the Market of HCV Treatments

NCT ID: NCT02961426

Last Updated: 2021-01-20

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 603 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-09-30
• Study Completion Date: 2024-03-31

Brief Summary

This is a Phase II/III, multicenter, multi-country, trial to assess the efficacy, safety, tolerance and pharmacokinetics of sofosbuvir plus ravidasvir for the treatment of HCV infection.

Detailed Description

This is a Phase II/III, multicenter, multi-country trial to assess the efficacy, safety, tolerance and pharmacokinetics of SOF-RDV for the treatment of HCV infection, across genotypes 1,2,3,6, among non-cirrhotic and cirrhotic with CTP class A, interferon/ribavirin naïve or experienced, HCV mono-infected and HCV/HIV co-infected subjects.

It will also study the pharmacokinetics of RDV and, in HCV/HIV co-infected subjects, possible drug-drug interactions with antiretrovirals.

The treatment duration will be 12 weeks for subjects with no cirrhosis (Metavir F0 to F3) and 24 weeks for subjects with compensated cirrhosis (Metavir F4, CTP class A).

The study is performed in 2 stages. Stage 1 has been completed. Efficacy and safety results from Stage 1 were reviewed and approved by the independent Data and Safety Monitoring Board (DSMB) which provided the recommendation to proceed with the study stage 2. On-going stage 2 aims to supplement Stage 1 results and provide additional information on the performance of SOF-RDV in the main genotypes found in Malaysia and Thailand.

Conditions

Hepatitis C

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

sofosbuvir + ravidasvir

12 weeks for non-cirrhotic patients, 24 weeks for cirrhotic patients

Group Type: EXPERIMENTAL

sofosbuvir + ravidasvir

Intervention Type: DRUG

combination of sofosbuvir + ravidasvir

Interventions

sofosbuvir + ravidasvir

combination of sofosbuvir + ravidasvir

Intervention Type: DRUG

Other Intervention Names

ravisdasvir: PPI-668

Eligibility Criteria

Inclusion Criteria

• Evidence of chronic HCV infection, defined as: Positive anti-HCV antibody or detectable HCV RNA or HCV genotype at least 6 months before screening and HCV viral load ≥10^4 IU/mL at the time of screening / In subjects without documented HCV test results 6 months before screening, chronic hepatitis C infection can be assumed if risk exposures occurred > 6 months prior to screening and HCV viral load ≥10^4 IU/mL at the time of screening.
• Willing and able to provide written informed consent.
• Men and women age ≥ 18 years and < 70 years.
• Body Mass Index (BMI) of 18 to 35 kg/m2.
• Intention to comply with the dosing instructions for study drug administration and able to complete the study schedule of assessments.
• Women with a negative pregnancy test at screening and baseline.
• Women of child bearing potential who accept a highly effective contraceptive method from at least 2 weeks prior to study day 1 until 1-month post-treatment. A woman is of non-child bearing potential if she (a) reached natural menopause determined retrospectively after 12 months of amenorrhea without any other obvious medical cause or (b) had procedures like bilateral tubal ligation or hysterectomy or bilateral oophorectomy.
• Subjects who are compliant in an opioid substitution maintenance program (e.g. with methadone or buprenorphine) may be included as long as there is no concern about study medications adherence and interaction or compliance to study schedules.

• HIV/HCV co-infected patients receiving cART fulfilling the below criteria are eligible for the study: Antiretroviral therapy (ART) should have been initiated at least 6 months prior to screening / Patient has to have been on the same protocol-approved ARV regimen for ≥ 8 weeks prior to screening and is expected to continue the current ARV regimen through the end of study / HIV ARVs: agents allowed in this study should be administered per the prescribing information in the package insert / Screening HIV RNA < 50 copies/mL / Screening CD4 cell count ≥ 100 cells/uL
• HIV/HCV co-infected patients not receiving cART: Screening CD4 cell count must be ≥ 500 cells/uL

Exclusion Criteria

• Decompensated cirrhosis defined as: Evidence of advanced stage liver cirrhosis and Child-Turcotte-Pugh (CTP) Class B or C or CTP score >6) or current/past history of decompensation including ascites, variceal bleeding, spontaneous bacterial peritonitis, or hepatic encephalopathy.
• Hepatocellular carcinoma: for all patients with cirrhosis, hepatocellular carcinoma (HCC), should be excluded by liver imaging within 6 months prior to screening, and this must continue periodically as in routine HCC surveillance.

• cirrhotic subjects with albumin < 2.8 g/dL
• direct bilirubin > 3xULN
• AST, ALT > 10xULN
• Low neutrophil count (≤599 cells/mm3), hemoglobin (<9.0 g/dL for male, <8.5 g/dL for female), platelets (<50000 cells/mm3 ) classified as ≥ Grade 3
• Patients with serum creatinine > 1.5 ULN or end stage renal disease
• Hepatitis B co-infection (HBsAg positive)
• Pregnancy, as documented by positive pregnancy tests at screening or baseline
• Breastfeeding
• Subjects currently receiving or unable to stop the use for at least 1 week prior to receiving the first dose of study drug any medications or herbal supplements known to be potent inhibitors or moderate inducers of cytochrome P450 (CYP) 3A4 or potent inducers of P-glycoprotein. This includes subjects who are on amiodarone or other contraindicated/excluded drugs.
• Participation in other clinical trials within 3 months.
• Any clinically significant findings or unstable condition during the screening, medical history or physical examination that, in the investigator's opinion, would compromise participation in this study as per standard guidelines and local practice. This could include patients with poorly controlled hypertension, asthma, diabetes, or other life-threatening conditions.
• Current or history of use within the preceding 6 months of immunosuppressive or immune-modulating agents. Corticosteroid used to treat any medical condition are allowed if systemic for not more than 2 weeks or if topical.
• History of solid organ or bone marrow transplantation.
• Any prior NS5A inhibitors therapy.
• Patients with significant cardiovascular conditions including:

• myocardial infarction within the previous 6 months or
• heart failure NYHA class III or IV
• history of Torsade de pointes
• Third degree heart block
• QTcF (Fridericia) value ≥ 450 milliseconds at Baseline
• Severe sinus bradycardia with a rate of under 50 beats per minute
• A sinus bradycardia with third degree atrioventricular block or with Mobitz II AV block
• Use of medications associated with QT prolongation concurrently or within the 30 days prior to Screening Visit, including: macrolides, antiarrhythmic agents, azoles, fluoroquinolones, and tricyclic anti-depressants. Commonly used and essential medications for this study population like methadone and/or efavirenz is allowed as long as the QTcF value at baseline is < 450 milliseconds.
• Self-reporting active injection drug use at screening (only for stage 2).

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 69 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ministry of Health, Malaysia

OTHER_GOV

Sponsor Role: collaborator

Ministry of Health, Thailand

OTHER_GOV

Sponsor Role: collaborator

National Science and Technology Development Agency, Thailand

OTHER_GOV

Sponsor Role: collaborator

Drugs for Neglected Diseases

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Isabelle Andrieux-Meyer, MD

Role: STUDY_DIRECTOR

Drugs for Neglected Diseases

Soek-Siam Tan, MD

Role: PRINCIPAL_INVESTIGATOR

Selayang Hospital

Satawat Thongsawat, MD

Role: PRINCIPAL_INVESTIGATOR

Chiang Mai Hospital

Locations

Hospital Sultanah Aminah

Johor Bahru, Johor, Malaysia

Hospital Raja Perempuan Zainab II

Kota Bharu, Kelantan, Malaysia

Department of Hepatology, Hospital Selayang

Batu Caves, Selangor, Malaysia

Hospital Sultanah Nur Zahirah

Kuala Terengganu, Terengganu, Malaysia

Department of Medicine/Gastroenterology, Hospital Sultanah Bahiyah

Alor Star, , Malaysia

Department of Medicine/ Gastroenterology, Hospital Ampang

Ampang, , Malaysia

Department of Medicine/Gastroenterology, University Malaya Medical Centre

Kuala Lumpur, , Malaysia

Hospital Tengku Ampuan Afzan ,Pusat Penyelidikan Klinikal,Aras Bawah ,Bangunan Pengurusan,Jalan Tanah Putih

Kuantan, , Malaysia

Department of Medicine/Infectious Disease, Hospital Sungai Buloh

Sungai Buloh, , Malaysia

King Chulalongkorn Memorial Hospital/HIV-NAT, Faculty of Medicine, Chulalongkorn University

Bangkok, , Thailand

Internal Medicine, Bamrasnaradura Infectious Diseases Institute

Bangkok, , Thailand

Internal Medicine unit, Medical Department, Nakornping Hospital

Chiang Mai, , Thailand

Gastroenterology unit, Department of Internal Medicine, Maharaj Nakorn Chiang Mai Hospital, Faculty of Medicine, Chiang Mai University

Chiang Mai, , Thailand

Countries

Malaysia; Thailand

References

Andrieux-Meyer I, Tan SS, Thanprasertsuk S, Salvadori N, Menetrey C, Simon F, Cressey TR, Said HRHM, Hassan MRA, Omar H, Tee HP, Chan WK, Kumar S, Thongsawat S, Thetket K, Avihingsanon A, Khemnark S, Yerly S, Ngo-Giang-Huong N, Siva S, Swanson A, Goyal V, Bompart F, Pecoul B, Murad S. Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial. Lancet Gastroenterol Hepatol. 2021 Jun;6(6):448-458. doi: 10.1016/S2468-1253(21)00031-5. Epub 2021 Apr 16.

Reference Type: DERIVED

PMID: 33865507 (View on PubMed)

Other Identifiers

DNDi-SOF/RDV-01-HCV

Identifier Type: -

Identifier Source: org_study_id